Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AbbVie Inc. Director's Dealing 2022

Mar 2, 2022

29755_dirs_2022-03-01_fbb1c549-cecd-49f3-9f68-d16da44d496d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2022-02-25

Reporting Person: Gosebruch Henry O (EVP, Chief Strategy Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-02-25 Common Stock, $0.01 par value F 30156 $149.54 Disposed 56623 Direct
2022-03-01 Common Stock, $0.01 par value S 5596 $147.5369 Disposed 51027 Direct
2022-03-01 Common Stock, $0.01 par value S 8303 $148.6224 Disposed 42724 Direct
2022-03-01 Common Stock, $0.01 par value S 1101 $149.1441 Disposed 41623 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock, $0.01 par value 78500 Indirect
Common Stock, $0.01 par value 3457 Indirect

Footnotes

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.89 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.94 to $148.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.95 to $149.40 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.

F5: Balance in AbbVie Savings program as of January 31, 2022.